Molecular Partners AG — FY2023 Form 20-F
Reporting period: Year ended December 31, 2023. This is an annual report, not a standalone 2023 fourth-quarter filing. Financial statements are prepared under IFRS and presented in Swiss francs (CHF); figures below are in CHF unless stated otherwise.
Business context
Molecular Partners is a clinical-stage biotechnology company developing DARPin therapeutics, with a strategic focus on oncology. It has no approved products and has never generated product-sales revenue. Its principal programs include MP0533 and MP0317, alongside its Radio-DARPin Therapy (RDT) pipeline. Revenue depends on collaboration payments, milestones and research services and may vary substantially between periods.
Key financial metrics
| Metric | FY2023 | FY2022 |
|---|---|---|
| Collaboration revenue | CHF 7.0 million | CHF 189.6 million |
| Research and development expenses | CHF 48.8 million | CHF 50.7 million |
| Selling, general and administrative expenses | CHF 19.4 million | CHF 22.2 million |
| Operating result | Loss of CHF 61.1 million | Profit of CHF 116.6 million |
| Net result attributable to shareholders | Loss of CHF 62.0 million | Profit of CHF 117.9 million |
| Net finance result | Loss of CHF 0.9 million | Gain of CHF 1.2 million |
| Cash used in operating activities | CHF 59.0 million | Cash generated of CHF 118.6 million |
| Cash, cash equivalents and short-term time deposits at year-end | CHF 186.9 million | CHF 249.1 million |
| Total assets | CHF 198.4 million | CHF 262.3 million |
| Shareholders’ equity | CHF 176.4 million | CHF 235.2 million |
Operating expenses were CHF 68.1 million, down from CHF 73.0 million. Personnel costs were CHF 40.0 million, and research consumables and project costs were CHF 15.9 million. The filing does not present a conventional product gross margin, as the company has no product sales. It reports no short- or long-term borrowings; lease liabilities were CHF 3.7 million, including CHF 1.2 million current. Management reported no material financing commitments such as credit lines or guarantees.
Changes versus the prior year
- Revenue fell by CHF 182.6 million. FY2022 included Novartis’s CHF 150 million option-exercise milestone for ensovibep, along with other collaboration-related income; FY2023 revenue came from the Novartis radioligand collaboration.
- Results swung from a CHF 117.9 million profit in 2022 to a CHF 62.0 million loss in 2023, mainly reflecting the absence of the prior-year milestone revenue while operating costs remained substantial.
- Operating cash flow shifted from CHF 118.6 million generated to CHF 59.0 million used. Investing cash flow was CHF 44.6 million positive in 2023, primarily from net movements in short-term deposits; this is not operating cash generation.
- Cash, cash equivalents and short-term deposits declined CHF 62.3 million year over year. The company reported cumulative losses of CHF 191.8 million.
- Headcount at year-end declined to 167.5 full-time equivalents from 175.3.
Outlook, commentary and material items
- Management estimated that existing cash and short-term deposits, together with anticipated collaboration funding, would fund operating and capital expenditure requirements well into 2026. This is an estimate based on assumptions; spending may exceed expectations, and the company expects losses and additional financing needs.
- MP0533 Phase 1/2a: At a December 2023 conference, the company reported initial data from 11 patients across four dosing regimens, with no dose-limiting toxicities observed. Reported drug-related events included Grade 1–2 infusion reactions and cytokine release syndrome; two responses were reported. These were early, small-sample results and may change. Dosing in cohort 6 was ongoing at the time of the report; the company planned further data in the first half of 2024 and proposed adding higher-dose cohorts.
- MP0317 Phase 1: Enrollment had concluded. Data from 46 patients were described as supporting CD40 activation and tumor-microenvironment changes, with a favorable safety profile reported across the planned dose range. The company expected to report the full dataset in the first half of 2024.
- In January 2024, the company and Orano Med agreed to co-develop 212Pb-based RDTs, including DLL3, sharing preclinical and clinical development costs. The company expected to advance DLL3 into IND-enabling studies in the first half of 2024 and anticipated clinical studies and first-in-human data in 2025; these are forward-looking plans, not completed milestones.
- In January 2024, Novartis returned ensovibep rights after the program’s clinical work had ended in 2022. The program remains terminated; the rights’ return does not indicate active development.
- Key risks include clinical and regulatory uncertainty, reliance on collaborators and contract manufacturers, future funding requirements, competition, and intellectual-property exposure. The foundational DARPin base patents expired by August 2023, although the company reports a broader portfolio of later platform, target-binding and product-specific patents.
- A putative U.S. securities class action concerning MP0310-related disclosures was dismissed without prejudice in February 2024; the plaintiff then stipulated to dismissal with prejudice, and the court closed the case on February 29, 2024.
- KPMG issued an unqualified audit opinion on the IFRS financial statements and reported no critical audit matters. Management concluded disclosure controls and internal control over financial reporting were effective at December 31, 2023; the auditor did not provide an internal-control attestation because of the company’s emerging-growth-company exemption.
Important facts for investors to verify
- Confirm the source, assumptions and sensitivity of management’s cash runway estimate through 2026, including planned R&D spending and anticipated collaboration funding.
- Review the complete MP0533 and MP0317 trial disclosures and subsequent updates, especially dose escalation, patient numbers, durability of responses, safety findings and any protocol changes.
- Check the financial-statement notes for revenue-recognition assumptions and the remaining CHF 4.3 million Novartis contract liability at year-end.
- Assess the terms, cost-sharing obligations, milestones and future commercialization arrangements for the Orano Med collaboration, which was announced after the reporting date.
- Evaluate potential dilution and financing capacity: the filing describes an ATM program of up to $100 million, reports no sales under it as of March 2024, and notes Swiss-law limits and shareholder rights affecting capital issuance.
- Consider the company’s reported 2023 PFIC status for U.S. tax purposes and obtain independent tax advice on the consequences for U.S. holders.